Skip to content Skip to footer
Subscribe Now
Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)
INSIGHTS+

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

Shots:With the indispensable transformations carried out over the years, the biopharma industry witnessed miraculous changes in operations, technology, and innovation. Such as inclination towards the Pharma 4.0 model, adoption of a multimodal building approach, and dependence on contract manufacturingWhile major companies like Johnson & Johnson, Roche, and Pfizer dominated the biopharma industry with…
April 13, 2023

Read more

Insights+: EMA Marketing Authorization of New Drugs in February 2023
INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in February 2023

Shots:The EMA approved 7 New Chemical Entity (NCE) and 5 Biologic Drugs in February 2023, leading to treatments for patients and advances in the healthcare industryIn February 2023, the major highlights drugs were Forxiga’s Approval for symptomatic chronic heart failure, Fintepla for adjunctive treatment of seizures associated with lennox-gastaut syndromePharmaShots has compiled…
March 23, 2023

Read more

BioPharma Top 20 2022
TOP 20

Top 20 Biopharma Deal Terminations of 2022 Based on Total Deal Value

Shots:Post M&A deals, companies often cannot sail through a few key aspects of the partnership, such as limited ownership, exorbitant recovery costs, and poor integration process, leading to deal terminations. The improperly executed expansion program also contributes significantly to the failed partnershipTo tackle such scenarios, companies are cautious enough to make backup plans beforehand…
March 22, 2023

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]